
Shares of healthcare firm Allurion Technologies ALUR.N rise 5.3% to $1.18 in early trading
Says patients using its swallowable gastric balloon followed by low-dose tirzepatide lost an average of 23% of their body weight over 12 months
Patients also saw lean body mass rise 14%, addressing muscle loss seen with GLP-1 drugs - ALUR
Says all 76 patients stayed on tirzepatide for full study duration, unlike typical high dropout rates
Tirzepatide, sold by Eli Lilly as Mounjaro for diabetes and Zepbound for obesity, is a GLP-1 drug that helps control blood sugar and appetite
Low-dose GLP-1 strategy aims to improve adherence and reduce side effects - ALUR
Including session's move, stock down ~90 YTD